Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials

IMPORTANCE: The prognostic impact of DNA mismatch repair (MMR) status in stage III colon cancer patients receiving FOLFOX (folinic acid, fluorouracil, and oxaliplatin) adjuvant chemotherapy remains controversial. OBJECTIVE: To determine the association of MMR status with disease-free survival (DFS)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Zaanan, Aziz, Shi, Qian, Taieb, Julien, Alberts, Steven R., Meyers, Jeffrey P., Smyrk, Thomas C., Julie, Catherine, Zawadi, Ayman, Tabernero, Josep, Mini, Enrico, Goldberg, Richard M., Folprecht, Gunnar, Van Laethem, Jean Luc, Le Malicot, Karine, Sargent, Daniel J., Laurent-Puig, Pierre, Sinicrope, Frank A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2017
Assuntos:
Brief Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5784452/
https://ncbi.nlm.nih.gov/pubmed/28983557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.2899
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados